These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32824349)

  • 1. Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease.
    Monserrat-Mesquida M; Quetglas-Llabrés M; Abbate M; Montemayor S; Mascaró CM; Casares M; Tejada S; Abete I; Zulet MA; Tur JA; Martínez JA; Sureda A
    Antioxidants (Basel); 2020 Aug; 9(8):. PubMed ID: 32824349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Adherence to the Mediterranean Diet after Lifestyle Intervention Improves Oxidative and Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease.
    Monserrat-Mesquida M; Quetglas-Llabrés M; Bouzas C; Montemayor S; Mascaró CM; Casares M; Llompart I; Ugarriza L; Martínez JA; Tur JA; Sureda A
    Antioxidants (Basel); 2022 Jul; 11(8):. PubMed ID: 35892642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Greater Improvement of Intrahepatic Fat Contents after 6 Months of Lifestyle Intervention Is Related to a Better Oxidative Stress and Inflammatory Status in Non-Alcoholic Fatty Liver Disease.
    Monserrat-Mesquida M; Quetglas-Llabrés M; Bouzas C; Montemayor S; Mascaró CM; Casares M; Llompart I; Gámez JM; Tejada S; Martínez JA; Tur JA; Sureda A
    Antioxidants (Basel); 2022 Jun; 11(7):. PubMed ID: 35883758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mediterranean Diet Improves Plasma Biomarkers Related to Oxidative Stress and Inflammatory Process in Patients with Non-Alcoholic Fatty Liver Disease.
    Quetglas-Llabrés MM; Monserrat-Mesquida M; Bouzas C; Llompart I; Mateos D; Casares M; Ugarriza L; Martínez JA; Tur JA; Sureda A
    Antioxidants (Basel); 2023 Mar; 12(4):. PubMed ID: 37107208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
    Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
    JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis.
    Andersson A; Kelly M; Imajo K; Nakajima A; Fallowfield JA; Hirschfield G; Pavlides M; Sanyal AJ; Noureddin M; Banerjee R; Dennis A; Harrison S
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2451-2461.e3. PubMed ID: 34626833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis.
    Cao W; Zhao C; Shen C; Wang Y
    PLoS One; 2013; 8(12):e82092. PubMed ID: 24324749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
    Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
    World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
    Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
    JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).
    Duseja A; Singh SP; De A; Madan K; Rao PN; Shukla A; Choudhuri G; Saigal S; Shalimar ; Arora A; Anand AC; Das A; Kumar A; Eapen CE; Devadas K; Shenoy KT; Panigrahi M; Wadhawan M; Rathi M; Kumar M; Choudhary NS; Saraf N; Nath P; Kar S; Alam S; Shah S; Nijhawan S; Acharya SK; Aggarwal V; Saraswat VA; Chawla YK
    J Clin Exp Hepatol; 2023; 13(2):273-302. PubMed ID: 36950481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis.
    Kumar A; Sharma A; Duseja A; Das A; Dhiman RK; Chawla YK; Kohli KK; Bhansali A
    J Clin Exp Hepatol; 2013 Mar; 3(1):12-8. PubMed ID: 25755466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Krag A; Karsdal MA; Nielsen MJ; Brockbank S; Cruwys S
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G410-G418. PubMed ID: 31905026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic Fatty Liver Disease Severity Is Related to Plasma Pro-Oxidative Biomarkers Rather Than Liver Tissue-Measured Nitrogen Metabolism Biomarkers in Population with Obesity and Metabolic Syndrome.
    Suárez-Cuenca JA; Domínguez-Pérez GA; Hernández-Muñóz RE; Hernández-Patricio A; Vera-Gómez E; Gutiérrez-Buendía JA; Salamanca-García M; Montoya-Ramírez J; Gaytán-Fuentes OF; Aranda-Rodríguez C; Rojas-Noverón AR; García S; Mondragón-Terán P
    Metab Syndr Relat Disord; 2023 Mar; 21(2):115-121. PubMed ID: 36787445
    [No Abstract]   [Full Text] [Related]  

  • 20. Pomegranate juice prevents development of non-alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammation.
    Noori M; Jafari B; Hekmatdoost A
    J Sci Food Agric; 2017 Jun; 97(8):2327-2332. PubMed ID: 27717115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.